Published in Q J Med on June 01, 1994
Primary central nervous system vasculitis: clinical experiences with 21 new European cases. Rheumatol Int (2009) 0.94
Isolated angiitis of central nervous system with pleocytosis in the cerebrospinal fluid. Postgrad Med J (1998) 0.75
The Role of Catheter Angiography in the Diagnosis of Central Nervous System Vasculitis. Interv Neurol (2016) 0.75
Primary central nervous system vasculitis mimicking brain tumour: case report and literature review. Rheumatol Int (2009) 0.75
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis (2008) 2.36
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Inflammatory myopathy--do we have adequate measures of the treatment response? J Rheumatol (1993) 2.04
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus (1998) 1.93
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis (2005) 1.84
Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum (1977) 1.82
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol (1996) 1.69
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol (1995) 1.61
Living with lupus: a prospective pan-Canadian study. J Rheumatol (2001) 1.56
Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood (1992) 1.55
Anomalies of the inferior vena cava. AJR Am J Roentgenol (1983) 1.52
Interrater reliability of the tender point criterion for fibromyalgia. J Rheumatol (1992) 1.44
Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol (1996) 1.42
Inhalable particles and pulmonary host defense: in vivo and in vitro effects of ambient air and combustion particles. Environ Res (1985) 1.42
Teplice program--the impact of air pollution on human health. Environ Health Perspect (1996) 1.41
Inflammatory myopathy--early diagnosis and management by serum myosin light chains measurements. Isr J Med Sci (1994) 1.40
Home air nicotine levels and urinary cotinine excretion in preschool children. Am Rev Respir Dis (1989) 1.40
CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet (2003) 1.38
Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol (2000) 1.37
Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med (1995) 1.36
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity. Genes Immun (2007) 1.32
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis (2013) 1.32
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol (1986) 1.28
Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum (1981) 1.27
HLA antigens in North American patients with Takayasu arteritis. Arthritis Rheum (1992) 1.27
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
Impaired antigen-specific suppressor cell activity in psoriasis and psoriatic arthritis. J Invest Dermatol (1981) 1.23
Effects of lymecycline on Mycoplasma pulmonis-induced arthritis in mice. Br J Exp Pathol (1978) 1.21
Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum (1993) 1.19
DNA adducts and personal air monitoring of carcinogenic polycyclic aromatic hydrocarbons in an environmentally exposed population. Carcinogenesis (1995) 1.17
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med (1979) 1.15
Airborne exposures to PAH and PM2.5 particles for road paving workers applying conventional asphalt and crumb rubber modified asphalt. J Expo Anal Environ Epidemiol (1998) 1.15
Systemic vasculitis following influenza vaccination--report of 3 cases and literature review. J Rheumatol (1993) 1.13
Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol (1994) 1.13
Modified catheter for percutaneous gastrojejunostomy. Radiology (1989) 1.10
DNA adducts as biomarkers for assessing exposure to polycyclic aromatic hydrocarbons in tissues from Xuan Wei women with high exposure to coal combustion emissions and high lung cancer mortality. Environ Health Perspect (1993) 1.09
Bioassay-directed chemical analysis in environmental research. Anal Chem (1986) 1.06
Impaired antigen-specific suppressor cell activity in patients with rheumatoid arthritis. Arthritis Rheum (1980) 1.05
Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. J Rheumatol (1988) 1.03
Lymphocyte subpopulations and reactivity to mitogens in patients with scleroderma. Clin Exp Immunol (1981) 1.03
Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum (1994) 1.02
Differences in detection of DNA adducts in the 32P-postlabelling assay after either 1-butanol extraction or nuclease P1 treatment. Cancer Lett (1989) 1.02
Evaluation of the mutagenicity and carcinogenicity of motor vehicle emissions in short-term bioassays. Environ Health Perspect (1983) 1.02
Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis Rheum (1997) 1.02
Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol (1996) 1.01
The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost (1991) 1.00
Molecular epidemiology of atherosclerosis. FASEB J (1997) 1.00
Cotinine analytical workshop report: consideration of analytical methods for determining cotinine in human body fluids as a measure of passive exposure to tobacco smoke. Environ Health Perspect (1990) 0.99
Malignancy in progressive systemic sclerosis--association with breast carcinoma. J Rheumatol (1983) 0.99
Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J Clin Invest (1997) 0.99
Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis (2010) 0.98
Spinal entheseal new bone formation: the early changes of spinal diffuse idiopathic skeletal hyperostosis. J Rheumatol (1983) 0.98
Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma. Rheumatology (Oxford) (2005) 0.98
Formation of DNA adducts in rat lung following chronic inhalation of diesel emissions, carbon black and titanium dioxide particles. Carcinogenesis (1994) 0.98
Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis. Thorax (1997) 0.97
Infections that cause vasculitis. Curr Opin Rheumatol (1992) 0.96
Outcome of polyarteritis nodosa and Churg-Strauss syndrome. An analysis of twenty-five patients. Arthritis Rheum (1994) 0.96
The articular manifestations of progressive systemic sclerosis (scleroderma). Ann Rheum Dis (1982) 0.95
Quality of life in systemic lupus erythematosus patients during more and less active disease states: differential contributors to mental and physical health. Arthritis Care Res (1999) 0.95
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis (2001) 0.95
Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol (1990) 0.93
HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. Arthritis Rheum (1987) 0.93
Standard reference materials for chemical and biological studies of complex environmental samples. Mutat Res (1992) 0.93
Antigen-specific suppressor cell activity in patients with scleroderma. J Rheumatol (1982) 0.92
Effect of T-cell deficiency on the chronicity of arthritis induced in mice by Mycoplasma pulmonis. Infect Immun (1980) 0.92
Mutagenicity of derivatives and metabolites of 1-nitropyrene: activation by rat liver S9 and bacterial enzymes. Mutat Res (1985) 0.92
Role of viable mycoplasmas in the pathogenesis of arthritis induced by M. pulmonis. Br J Exp Pathol (1981) 0.92
DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine. Mutat Res (1996) 0.92
Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies. Clin Exp Immunol (1982) 0.91
Dose-related differences in DNA adduct levels in rodent tissues following skin application of complex mixtures from air pollution sources. Carcinogenesis (1990) 0.91
Cranial computerized tomography in systemic lupus erythematosus. J Rheumatol (1983) 0.91
Polycyclic aromatic hydrocarbons (PAHs), nitro-PAHs and related environmental compounds: biological markers of exposure and effects. Environ Health Perspect (1996) 0.91
Hypotension with oliguria: a side-effect of azathioprine. Arthritis Rheum (1981) 0.91
Role of antibody in the protection of mice from arthritis induced by Mycoplasma pulmonis. Clin Exp Immunol (1982) 0.90
A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol (2007) 0.90
Comparative characterization of organic emissions from diesel particles, coke oven mains, roofing tar vapors and cigarette smoke condensate. Int J Environ Anal Chem (1986) 0.90
Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med (1992) 0.90
Role of endotoxin in tumor necrosis factor alpha expression from alveolar macrophages treated with urban air particles. Exp Lung Res (1997) 0.90
Biomarker studies in northern Bohemia. Environ Health Perspect (1996) 0.90
The role of corpus cavernosography in acute "fracture" of the penis. Radiology (1982) 0.89
Eosinophilic fasciitis and aplastic anaemia. J Rheumatol (1981) 0.89
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. Arthritis Care Res (Hoboken) (2011) 0.88
Interleukin abnormalities in recently active rheumatoid arthritis. J Rheumatol (1984) 0.88
Development of a standard reference material for diesel mutagenicity in the Salmonella plate incorporation assay. Mutat Res (1997) 0.88
Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis. Exp Clin Immunogenet (1997) 0.88
Improvement in the diagnostic potential of 32P-postlabeling analysis demonstrated by the selective formation and comparative analysis of nitrated-PAH-derived adducts arising from diesel particle extracts. Carcinogenesis (1991) 0.88
Binding of 1-nitro[14C]pyrene to DNA and protein in cultured lung macrophages and respiratory tissues. Cancer Lett (1983) 0.87
Mixed leukocyte reaction (MLR) in rheumatoid arthritis: dose-response kinetics. Clin Immunol Immunopathol (1976) 0.87